Denali Therapeutics Inc.

BOVESPA:D2NL34 Stock Report

Market Cap: R$20.4b

Denali Therapeutics Management

Management criteria checks 3/4

Denali Therapeutics' CEO is Ryan Watts, appointed in Aug 2015, has a tenure of 9.25 years. total yearly compensation is $7.88M, comprised of 8.5% salary and 91.5% bonuses, including company stock and options. directly owns 1.56% of the company’s shares, worth R$318.43M. The average tenure of the management team and the board of directors is 5.8 years and 8.1 years respectively.

Key information

Ryan Watts

Chief executive officer

US$7.9m

Total compensation

CEO salary percentage8.5%
CEO tenure9.3yrs
CEO ownership1.6%
Management average tenure5.8yrs
Board average tenure8.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ryan Watts's remuneration changed compared to Denali Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$427m

Jun 30 2024n/an/a

-US$420m

Mar 31 2024n/an/a

-US$137m

Dec 31 2023US$8mUS$670k

-US$145m

Sep 30 2023n/an/a

-US$124m

Jun 30 2023n/an/a

-US$128m

Mar 31 2023n/an/a

-US$371m

Dec 31 2022US$9mUS$645k

-US$326m

Sep 30 2022n/an/a

-US$303m

Jun 30 2022n/an/a

-US$284m

Mar 31 2022n/an/a

-US$286m

Dec 31 2021US$13mUS$610k

-US$291m

Sep 30 2021n/an/a

US$30m

Jun 30 2021n/an/a

US$56m

Mar 31 2021n/an/a

US$58m

Dec 31 2020US$9mUS$589k

US$71m

Sep 30 2020n/an/a

-US$228m

Jun 30 2020n/an/a

-US$216m

Mar 31 2020n/an/a

-US$215m

Dec 31 2019US$5mUS$567k

-US$198m

Sep 30 2019n/an/a

-US$66m

Jun 30 2019n/an/a

-US$55m

Mar 31 2019n/an/a

-US$52m

Dec 31 2018US$6mUS$545k

-US$36m

Sep 30 2018n/an/a

-US$137m

Jun 30 2018n/an/a

-US$123m

Mar 31 2018n/an/a

-US$91m

Dec 31 2017US$1mUS$481k

-US$88m

Compensation vs Market: Ryan's total compensation ($USD7.88M) is above average for companies of similar size in the BR market ($USD1.26M).

Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.


CEO

Ryan Watts (48 yo)

9.3yrs

Tenure

US$7,879,267

Compensation

Dr. Ryan J. Watts, Ph D., serves as Director at PEEL Therapeutics, Inc. since February 2023. He is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since Au...


Leadership Team

NamePositionTenureCompensationOwnership
Ryan Watts
Co-Founder9.3yrsUS$7.88m1.56%
R$ 318.4m
Alexander Schuth
Co-Founder9.7yrsUS$4.17m0.41%
R$ 82.8m
Marc Tessier-Lavigne
Co-Founder & Independent Directorno dataUS$431.93k1.47%
R$ 300.0m
Carole Ho
Chief Medical Officer & Head of Development9.4yrsUS$4.17m0.14%
R$ 29.6m
Tyler Nielsen
Senior Vice President of Corporate Financeno datano datano data
Dana Andersen
Chief Technical and Manufacturing Officer6.3yrsno datano data
Joe Lewcock
Chief Scientific Officer4.3yrsno datano data
Laura Hansen
Vice President of Investor Relations4.8yrsno datano data
Chris Walsh
General Counsel5.8yrsno datano data
Mark Rowen
Vice President of Corporate Development1.8yrsno datano data
Cindy Dunkle
Chief People Officerno datano datano data
Katie Peng
Chief Commercial Officer3.2yrsno datano data

5.8yrs

Average Tenure

51yo

Average Age

Experienced Management: D2NL34's management team is seasoned and experienced (5.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ryan Watts
Co-Founder9.7yrsUS$7.88m1.56%
R$ 318.4m
Marc Tessier-Lavigne
Co-Founder & Independent Director9.7yrsUS$431.93k1.47%
R$ 300.0m
Vicki Sato
Independent Chairperson9.6yrsUS$459.43k0.073%
R$ 14.9m
Jay Flatley
Independent Director9.6yrsUS$444.43k0.24%
R$ 48.4m
Eric Reiman
Member of Scientific Advisory Boardno datano datano data
David Schenkein
Independent Director9.6yrsUS$439.43k0.042%
R$ 8.6m
David Holtzman
Member of Scientific Advisory Board4yrsno datano data
Peter Klein
Independent Director6.7yrsUS$439.43k0.011%
R$ 2.2m
Jennifer Cook
Independent Director6yrsUS$429.43k0.0098%
R$ 2.0m
Steve Krognes
Director2.5yrsUS$419.43k0.57%
R$ 117.6m
Scott Biller
Member of Scientific Advisory Boardno datano datano data
Stacie Weninger
Member of Scientific Advisory Board3.8yrsno datano data

8.1yrs

Average Tenure

64yo

Average Age

Experienced Board: D2NL34's board of directors are considered experienced (8.1 years average tenure).